Sarepta Therapeutics (SRPT) is a gene therapy innovator delivering transformative treatments for rare neuromuscular diseases with a 2024 revenue surge to $1.90B and a return to profitability.
Investors may favor Sarepta due to its successful transition to profitability and strong revenue growth trajectory driven by blockbuster gene therapies. The company's diversified portfolio and strategic licensing deals provide multiple avenues for value creation as new products enter the market. With a substantial cash reserve, Sarepta is well-positioned to weather R&D cycles without immediate dilution.
Concerns persist regarding the sustainability of revenue growth if key therapies face competition or regulatory hurdles that reduce pricing power. The company's reliance on a small number of high-cost products exposes it to significant market concentration risk. Ongoing clinical trial failures or adverse events could severely impact investor sentiment and stock valuation.
Sarepta Therapeutics is a leading biopharmaceutical company focused on developing and commercializing gene therapies and small molecule drugs primarily for rare neuromuscular disorders. The company's core portfolio includes Syfovre for Galloway-Mowat syndrome, Elevidys for Duchenne muscular dystrophy, and Viltepso for mitochondrial neurogastrointestinal encephalomyopathy, serving a global patient base through specialized healthcare markets.
Sarepta achieved a notable turnaround in 2024 with $1.90B in revenue and $235.2M net profit, contrasting sharply with prior years of losses. Cash flow from operations improved significantly despite high non-cash adjustments, while the company maintained a healthy cash balance of $1.12B to fund future development.
The rare disease sector is experiencing rapid expansion as gene therapies become more accessible and regulatory pathways evolve to support innovative treatments. Sarepta operates in a niche but high-value environment where patient populations are small but willing to pay premium prices for life-changing interventions. Competition from big pharma and emerging biotech firms continues to intensify, driving the need for continuous innovation.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $933.0M | $1.24B | $1.90B |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $933.0M | $1.24B | $1.90B |
| Operating Expenses | $1.47B | $1.51B | $1.68B |
| Operating Income | $-536.2M | $-267.8M | $218.1M |
| G&A | $451.4M | $481.9M | $557.9M |
| Stock-Based Comp | $233.0M | $182.5M | $184.3M |
| D&A | $41.9M | $44.4M | $37.7M |
| Depreciation | $40.0M | $42.5M | $42.7M |
| Amortization | $714.0K | $1.6M | $2.4M |
| Other OpEx | $1.02B | $1.03B | $1.13B |
| Non-Operating Income | $-153.8M | $-252.3M | $42.7M |
| Interest Expense | $53.2M | $22.0M | $-18.4M |
| Interest Income | $16.5M | $36.3M | $30.6M |
| Pre-Tax Income | $-690.0M | $-520.1M | $260.8M |
| Income Tax | $13.5M | $15.9M | $25.5M |
| Continuing Ops | $-703.5M | $-536.0M | $235.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-703.5M | $-536.0M | $235.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-703.5M | $-536.0M | $235.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $2.56B | $2.58B | $3.07B |
| Cash & Equivalents | $966.8M | $428.4M | $1.10B |
| Marketable Securities | $1.02B | $1.25B | $251.8M |
| Accounts Receivable | $214.6M | $400.3M | $602.0M |
| Inventory | $204.0M | $322.9M | $750.0M |
| Other Current Assets | $149.9M | $179.9M | $366.7M |
| Long-Term Assets | $570.5M | $685.2M | $889.7M |
| PP&E (Net) | $180.0M | $227.2M | $340.3M |
| Operating Leases | $65.0M | $130.0M | $148.3M |
| LT Investments | — | — | $133.2M |
| Other LT Assets | $325.5M | $328.1M | $267.9M |
| Total Assets | $3.13B | $3.26B | $3.96B |
| Current Liabilities | $619.6M | $653.7M | $731.7M |
| Accounts Payable | $95.9M | $164.9M | $214.4M |
| Current Debt | — | $105.5M | $0 |
| Current Leases | $15.5M | $17.8M | $13.3M |
| Deferred Revenue | $89.2M | $50.4M | $130.3M |
| Other Current Liab | $0 | $0 | $200.0K |
| Long-Term Liabilities | $2.12B | $1.75B | $1.70B |
| LT Operating Leases | $57.6M | $141.0M | $192.5M |
| Other LT Liab | $1.58B | $1.17B | $1.19B |
| Total Liabilities | $2.74B | $2.41B | $2.44B |
| Shareholders' Equity | $384.9M | $859.3M | $1.53B |
| Retained Earnings | $-3.91B | $-4.45B | $-4.21B |
| AOCI | $-1.7M | $918.0K | $-218.0K |
| Total L&E | $3.13B | $3.26B | $3.96B |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-703.5M | $-536.0M | $235.2M |
| Non-Cash Adjustments | $369.6M | $-222.3M | $-1.02B |
| Working Capital Changes | $8.6M | $257.3M | $574.3M |
| Cash from Operations | $-325.3M | $-501.0M | $-205.8M |
| Capital Expenditures | $30.8M | $76.1M | $137.0M |
| Cash from Investing | $-1.05B | $-165.8M | $755.6M |
| Debt Issuances | $0 | — | — |
| Cash from Financing | $232.5M | $125.0M | $124.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-1.14B | $-541.8M | $674.6M |
| Beginning Cash | $2.13B | $985.8M | $444.0M |
| Ending Cash | $985.8M | $444.0M | $1.12B |
The company operates primarily through its proprietary drug portfolio, generating revenue from commercial sales of approved therapies like Elevidys and Syfovre. Operations are further supported by licensing agreements, such as the collaboration with Mitsubishi Tanabe Pharma for Viltepso, which contributes to international expansion and revenue diversification beyond direct commercial sales.
Regulatory uncertainty surrounding the approval of Elevidys remains a critical risk given its significant contribution to recent revenue growth. High patient acquisition costs and potential reimbursement challenges in key markets could impact future cash flows from gene therapies. The company faces ongoing R&D expenses as it advances its pipeline, which may result in volatile earnings before products reach commercial maturity.
Sarepta possesses deep proprietary expertise in RNA-targeted therapeutics, granting it a technological moat in treating rare genetic mutations. The company holds robust intellectual property rights across its pipeline, securing long-term market exclusivity for orphan drugs with limited competition. Strong strategic partnerships allow Sarepta to leverage global manufacturing and distribution networks without heavy capital expenditure on production facilities.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.